News ReleaseView printer-friendly version << Back
Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®
Award recognizes plastic surgeon for "Best Use of Opioid Alternatives"
An early adopter of EXPAREL, Dr. Baxter has been using the non-opioid local analgesic for several months to control postsurgical pain in patients undergoing abdominoplasty and breast augmentation procedures, which he says has reduced his opioid use by at least 50 percent.
"It has always been important to me to stay on the cutting edge of any advances that can help improve my patients' postsurgical experience and control their discomfort during the healing process," said Dr. Baxter, owner and medical director of
Also at the OR Excellence conference,
"As an anesthesiologist and pain specialist, I recognize that pain management begins both before and during the anesthetic - not just after the operation," said Dr. Viscusi. "Although they can be effective analgesics, opioids have problematic side effects. I always try to minimize reliance on opioids with a foundation of non-opioid analgesics such as local anesthetics, like EXPAREL; acetaminophen; and non-steroidal anti-inflammatory agents."
EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia. Following commercial availability in April, the product has been used in more than 20,000 patients.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated for administration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at www.EXPAREL.com.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Pure Communications, Inc.
Susan Heins, 864-286-9597